

Contact: Bryan Thomas
thomas@smdiscovery.com
Phone 720-635-0247

Geoff Lewis named SMDG's Senior VP, Legal Counsel

(Denver, CO, September 20, 2018) – SMDG (S.M. Discovery Group), a life science bio-nanotechnology company that has developed an innovative nano-delivery system for unimpeded penetration of physiological barriers including the Blood-Brain Barrier, announces the addition of Geoff Lewis as its Senior Vice President, Legal Counsel.

Lewis brings over a billion dollars of transactional experience in securities, IPOs, mergers & acquisitions, corporate finance, joint ventures and contracts with one of the largest corporate law firms in the world and three NYSE-listed companies.

Lewis will play an important role in helping SMDG to position itself for the next stage of business development, partnerships and fundraising, according to Dr. Shadi Farhangrazi, SMDG CEO and co-founder. "Geoff's vast experience in M&A, securities and corporate finance will be significant in assisting SMDG. We will greatly rely on his legal and business advice as we position the company to achieve our strategic milestones" said Farhangrazi.

Lewis was most recently President of RE/MAX International Holdings, an international franchise and marketing company with a presence in over 100 countries. He was instrumental in taking RE/MAX public on the NYSE in 2013. He has also served as Vice President Corporate Development and General Counsel of Hyster-Yale Materials Handling, Inc., a market leading global manufacturing company (\$2 billion) (NYSE: HY) and prior to that Vice President, General Counsel of American Health Properties, Inc., a NYSE-listed real estate investment trust that owned acute-care hospitals.

Lewis received a law degree from the University of Virginia, an MBA from the University of Colorado and a B.A. from Brigham Young University. He is currently Chairman

of the Board of Volunteers of America, Colorado Branch, and a non-profit organization serving the homeless, seniors, children, women and veterans.

SMDG has developed a proprietary nano-platform for “active (or receptor)-targeting” of physiological barriers. Based on industry “simple- and safe-by-design” standards and a decade of research from one of the top nanomedicine laboratories in Europe, its innovative, patent-protected platform is a versatile and multifunctional disruptive technology that overcomes specificity and target binding avidity limitations in “active-targeting” with particulate drug carriers. SMDG’s technology has proven to be highly efficacious in crossing biological barriers (including the Blood-Brain Barrier) without inducing any toxicity effects. SMDG is currently focusing on its Series A fundraising round.
